These findings implicate an alteration in PAR activity in ALS, and suggest that PARP-1/2 inhibitors, which are in use for cancer treatment, might be repurposed for TDP-43-associated disorders. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.